Skip to main content

Table 1 Overall INDEPTH baseline patient characteristics

From: Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis

Parameter

Placebo (n = 1,231)

DrotAA (n = 3,228)

p

Age, years (mean ± SD)

60.3 ± 16.5

59.5 ± 17.0

0.15a

   <65 (%)

55.2

54.5

0.84b

   65 – 74 (%)

24.2

25.1

 

   ≥75(%)

20.6

20.5

 

Male sex (%)

57.6

57.6

0.99b

Caucasian ethnicity (%)

79.4

88.3

<0.0001b

APACHE II score (mean ± SD)

24.6 ± 7.8

22.7 ± 7.5

0.0001a

   <25 (%)

53.2

60.4

<0.0001b

   ≥25(%)

46.8

39.6

 

Number of ODs (mean ± SD)

2.4 ± 1.1

2.6 ± 1.1

<0.0001a

   1 (%)

20.6

18.1

0.07b

   ≥2(%)

79.4

81.9

 

Time from first OD to start of infusion (mean ± SD)

23.9 ± 111.4

23.8 ± 13.6

0.97a

Mechanical ventilation (%)

78.3

79.7

0.31b

Vasopressors (%)

64.1

70.2

0.0002b

Recent surgery (%)

33.1

35.1

0.24b

  1. APACHE, Acute Physiology and Chronic Health Evaluation; DrotAA, drotrecogin alfa (activated); INDEPTH, International Integrated Database for the Evaluation of Severe Sepsis and Drotrecogin alfa (activated) Therapy; OD, organ dysfunction. aStudent's t test; bχ2 test.